UVE:NYSEUNIVERSAL INSURANCE HOLDINGS INC Analysis
Data as of 2026-07-29 - not real-time
$45.02
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Universal Insurance Holdings is trading near its 52‑week high of $45.15 with the 20‑day SMA ($41.11) comfortably above the 50‑day SMA ($39.47) and the 200‑day SMA ($34.82), confirming a bullish technical backdrop. RSI sits at 66.8, indicating strong momentum but still below overbought territory, while the MACD histogram is positive and the MACD line exceeds its signal, reinforcing short‑term upside potential. The stock’s trailing PE of 5.9 is dramatically lower than the industry average of 17.9, and the DCF model suggests a fair value far above the current price, flagging a clear valuation gap. Fundamentally, the company posts a ROE of 38.9% and a profit margin of 12.2%, with cash generation (operating cash flow $349.5M) easily covering its modest $100.3M debt load, yielding a debt‑to‑equity of 17.1%. Dividend sustainability looks strong, with a 1.48% yield, a payout ratio of just 8.4%, and ample cash reserves. Recent news highlights a regular cash dividend declaration and robust adjusted ROE growth, while the upcoming Q2 earnings release could add further catalyst. However, volatility is high at 51.8% over the past 30 days, though beta is very low (0.13), suggesting market moves are more company‑specific than market‑driven.
Given the confluence of bullish technical signals, deep valuation discount, solid profitability, and a sustainable dividend, the stock appears positioned for upside in the near term. Medium‑term performance may hinge on the Q2 results and whether the price can break through the $45.15 resistance. Over the long haul, the company’s strong cash flow, low leverage, and consistent dividend policy support a buy‑and‑hold thesis, provided investors are comfortable with the current volatility profile.
Given the confluence of bullish technical signals, deep valuation discount, solid profitability, and a sustainable dividend, the stock appears positioned for upside in the near term. Medium‑term performance may hinge on the Q2 results and whether the price can break through the $45.15 resistance. Over the long haul, the company’s strong cash flow, low leverage, and consistent dividend policy support a buy‑and‑hold thesis, provided investors are comfortable with the current volatility profile.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish SMA crossover and positive MACD
- Substantial valuation discount (PE 5.9 vs industry 17.9)
- Sustainable dividend with low payout ratio
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Upcoming Q2 earnings release as catalyst
- Price approaching resistance at $45.15
- High short‑term volatility may cause price swings
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong ROE and cash generation
- Low leverage and ample liquidity
- Attractive dividend yield and sustainability
Key Metrics & Analysis
Financial Health
Revenue Growth-0.30%
Profit Margin12.22%
P/E Ratio5.9
ROE38.88%
ROA6.06%
Debt/Equity17.15
P/B Ratio2.1
Op. Cash Flow$349.5M
Free Cash Flow$338.5M
Industry P/E17.9
Technical Analysis
TrendBullish
RSI66.8
Support$36.59
Resistance$45.15
MA 20$41.11
MA 50$39.47
MA 200$34.82
MACDBullish
VolumeStable
Fear & Greed Index84.54
Valuation
Fair Value$174.67
Target Price$45.00
Upside/Downside-0.04%
GradeUndervalued
TypeValue
Dividend Yield1.48%
Risk Assessment
Beta0.13
Volatility51.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.